WHO
meets over new variant; drugmakers expect to confirm vaccine effective against
it
The World Health Organization (WHO) has
called a meeting of members for Wednesday to discuss strategies to counter a
new, more infectious variant of the coronavirus that has emerged in Britain. A
spokeswoman said the meeting was designed to help with information-sharing.
At least four drugmakers expect their
COVID-19 vaccines will be effective against the new fast-spreading variant and
are performing tests that should provide confirmation in a few weeks. The
mutation known as the B.1.1.7 lineage may be up to 70% more infectious and more
of a concern for children.
In the event that the variant presents
vaccine developers with an unexpected challenge, an advantage of Pfizer and
BioNTech’s mRNA vaccine is that scientists can quickly re-engineer genetic
material in the shot to match that of the mutated protein, whereas modifying
traditional vaccines would require extra steps.
S. Korea logs second-highest daily
coronavirus tally
South Korea reported on Wednesday its
second-highest daily tally of coronavirus cases as a survey underscored growing
public dissatisfaction with President Moon Jae-in’s handling of the latest wave
of infections hitting the country.
According to a poll by research firm
Realmeter published on Wednesday, six in ten South Koreans believe urgency
should be prioritised over safety when it comes to COVID-19 vaccines and that
inoculations should begin as soon as possible given the rapid surge in new
cases.
Domestic media has lambasted the
government’s approach to securing vaccines as too relaxed and overly reliant on
domestic vaccines which will take more time than overseas options.
Vaccine stirs rare hesitation in nearly
virus-free Singapore
As Singapore prepares to roll out COVID-19
vaccinations, its striking success in controlling the virus is making some
question whether they should take the jabs. In a city-state where compliance
with the authorities is generally high, some Singaporeans fear potential side effects
- even if minimal - are not worth the risk when daily cases are almost zero and
fatalities are among the world’s lowest.
But the government is keen to open more of
the economy with the help of the vaccine in a country dependent on travel and
trade and preparing to host the World Economic Forum’s annual gathering next
year.
To show the vaccine is safe, Prime Minister
Lee Hsien Loong, 68, said he and his colleagues would be among the early
recipients of the shots. They will be free, voluntary and given first to
healthcare workers and the elderly. The first shipment of the Pfizer-BioNTech
vaccine arrived this week and Singapore expects to have enough vaccines for all
5.7 million people by the third quarter of 2021.
More
https://uk.reuters.com/article/uk-health-coronavirus-snapshot/what-you-need-to-know-about-the-coronavirus-right-now-idUKKBN28X0GX?il=0
EU to get 12.5 million doses of
BioNTech-Pfizer COVID-19 vaccine by year-end
December 22,
2020 9:34 AM
ZURICH/FRANKFURT (Reuters) -BioNTech and U.S. drugmaker Pfizer will
supply 12.5 million doses of their COVID-19 vaccine to the European Union by
the end of the year, the German company said on Tuesday.
That is more than half the 20 million doses expected to be delivered to
the United States before the end of the year, BioNTech’s chief business
officer, Sean Marett, told a briefing.
With two shots administered three weeks apart, the EU deliveries would
be enough to vaccinate 6.25 million people as the companies gear up to deliver
the first shots following regulatory approval on Monday.
The 27 EU member states that want shots will receive them within five
days, Marett told a briefing.
The German biotech company plans to start production in February at its site
in Marburg, Germany, chief financial officer Sierk Poetting said in the same
briefing.
It has said previously the facility, which it bought in September, would
eventually have an annual production capacity up to 750 million doses.
https://uk.reuters.com/article/uk-health-coronavirus-germany-biontech-s/eu-to-get-12-5-million-doses-of-biontech-pfizer-covid-19-vaccine-by-year-end-idUKKBN28W0YZ?il=0
Pfizer, Moderna testing their
vaccines against UK coronavirus variant - CNN
December 22,
2020 10:46 AM
(Reuters) - Pfizer Inc and Moderna Inc are
testing their COVID-19 vaccines against the new fast-spreading version of the
virus that has emerged in Britain, CNN reported on Tuesday.
Moderna expects immunity from its vaccine to
protect against the variants and is performing more tests in the coming weeks
to confirm, the company said in a statement to CNN. cnn.it/38qpbFl
Pfizer said it is “generating data” on how
well blood samples from people immunized with its vaccine “may be able to
neutralize the new strain from the UK,” according to the report.
Pfizer and Moderna did not immediately
respond to Reuters’ requests for comment.
The discovery of the new strain sowed a
fresh wave of panic in a pandemic that has killed about 1.7 million people and
infected more than 77.15 million worldwide.
The main worry is that the new variant is
40%-70% more transmissible.
Scientists have
said there’s no evidence that vaccines currently being deployed in the United
Kingdom - made by Pfizer and BioNTech - or other COVID-19 shots in development
will not protect against this variant, known as the B.1.1.7 lineage.
https://uk.reuters.com/article/uk-health-coronavirus-pfizer-moderna/pfizer-moderna-testing-their-vaccines-against-uk-coronavirus-variant-cnn-idUKKBN28W149?il=0
Next, some vaccine links
kindly sent along from a LIR reader in Canada. The links come from a most
informative update from Stanford Hospital in California.
World
Health Organization - Landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
NY
Times Coronavirus Vaccine Tracker. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
Stanford
Website. https://racetoacure.stanford.edu/clinical-trials/132
Regulatory
Focus COVID-19 vaccine tracker. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
Some other useful Covid links.
Johns Hopkins Coronavirus
resource centre
https://coronavirus.jhu.edu/map.html
Rt Covid-19
https://rt.live/
Covid19info.live
https://wuflu.live/
Centers for Disease Control
Coronavirus
https://www.cdc.gov/coronavirus/2019-ncov/index.html
The Spectator Covid-19 data tracker (UK)
https://data.spectator.co.uk/city/national
Technology Update.
With events happening
fast in the development of solar power and graphene, I’ve added this section.
Updates as they get reported.
Flexible and powerful electronics
Date: December 16, 2020
Source: University of Tsukuba
Summary: Researchers have developed a method for
optimizing the electrical properties of carbon-based conductors by turning them
into an ionic gel. This work may open the way for cheap, highly efficient
sensors that can be printed on flexible surfaces.
Researchers at the University of Tsukuba have created a new carbon-based
electrical device, π-ion gel transistors (PIGTs), by using an ionic gel made of
a conductive polymer. This work may lead to cheaper and more reliable flexible
printable electronics.
Organic conductors, which are carbon-based polymers that can carry
electrical currents, have the potential to radically change the way electronic
devices are manufactured. These conductors have properties that can be tuned
via chemical modification and may be easily printed as circuits. Compared with
current silicon solar panels and transistors, systems based on organic
conductors could be flexible and easier to install. However, their electrical
conductivity can be drastically reduced if the conjugated polymer chains become
disordered because of incorrect processing, which greatly limits their ability
to compete with existing technologies.
Now, a team of researchers led by the University of Tsukuba have
formulated a novel method for preserving the electrical properties of organic
conductors by forming an "ion gel." In this case, the solvent around
the poly(para-phenyleneethynylene) (PPE) chains was replaced with an ionic
liquid, which then turned into a gel. Using confocal fluorescent microscopy and
scanning electron microscopy, the researchers were able to verify the
morphology of the organic conductor.
"We showed that the internal structure of our π-ion gel is a
nanofiber network of PPE, which is very good at reliably conducting
electricity" says author Professor Yohei Yamamoto.
In addition to acting as wires for delocalized electrons, the polymer
chains direct the flow of mobile ions, which can help move charge-carriers to
the carbon rings. This allows current to flow through the entire volume of the
device. The resulting transistor can switch on and off in response to voltage
changes in less than 20 microseconds -- which is faster than any previous device
of this type.
"We plan to use this advance in supramolecular chemistry and
organic electronics to design a whole arrange of flexible electronic
devices," explains Professor Yamamoto. The fast response time and high
conductivity open the way for flexible sensors that enjoy the ease of
fabrication associated with organic conductors, without sacrificing speed or
performance.
https://www.sciencedaily.com/releases/2020/12/201216104640.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fmatter_energy%2Fgraphene+%28Graphene+News+--+ScienceDaily%29
No society can surely be flourishing and happy, of which the far
greater part of the members are poor and miserable.
Adam Smith.
No comments:
Post a Comment